Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18

Akbas S. H., Ozben T., Alper O., Uğur A., Yucel G., Lüleci G.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, cilt.39, sa.6, ss.487-490, 2001 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 6
  • Basım Tarihi: 2001
  • Doi Numarası: 10.1515/cclm.2001.080
  • Dergi Adı: CLINICAL CHEMISTRY AND LABORATORY MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.487-490
  • Anahtar Kelimeler: Down's syndrome, trisomy 18, screening : maternal serum, alpha-fetoprotein, estradiol, unconjugated, human chorionic gonadotropin, HUMAN CHORIONIC-GONADOTROPIN, DIMERIC INHIBIN-A, ALPHA-FETOPROTEIN, FETAL ANEUPLOIDY, MARKERS, AGE
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Maternal serum screening identifies women at an increased risk of a pregnancy with Down's syndrome or trisomy 18 or an open neural tube defect. The triple test, consisting of maternal serum alpha -fetoprotein, unconjugated estriol and human chorionic gonadotropin was carried out by a chemiluminescence immunoassay method in our laboratory. The study consisted of 373 pregnant women. The gestational range for the study group was 14-22 weeks. The mean maternal age for the study group was 28.53 +/- 5.46 years (range 17.4 to 43.5 years); 9.1% of the women were considered at high risk for Down's syndrome based on the test results. In our study the detection rate for Down's syndrome by prenatal karyotyping was 66.6%. Maternal serum screening allows reduction of the number of women requiring amniocentesis without a significant decrease in the detection rate.